Published in Cancer Weekly, June 30th, 1997
The study is being conducted at the Cancer Center of the University of Pennsylvania by Dr. Joseph Treat and studies the effects of LED in several types of solid tumors including breast, lung, prostate, and leukemia in patients who have failed standard treatments.
NeoPharm's proprietary liposomes are designed to counteract the genetic Multiple Drug Resistance (MDR) problem which is so prevalent in cancer patients. Pre-clinical work has shown that NeoPharm's liposome blocks the function of p-glycoprotein which is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.